Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women

NCT01508858 · Completed

Last updated 2026-05-28

This study tested how liraglutide affects the levels of an oral contraceptive in postmenopausal women with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 21 people

Who can join Ages 18–99 · female only

Timeline Started 2006-11 · est. completion 2007-04

Where 1 site · Sweden

What this study is testing ClinicalTrials.gov NCT01508858 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to investigate if liraglutide changes AUC (area under the curve) of ethinylestradiol and levonorgestrel administered as a combination contraceptive drug (Neovletta®).

Treatments tested

liraglutide Drug

Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
placebo Drug

Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
levonorgestrel / ethinylestradiol Drug

One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period

Main thing measured	AUC of ethinylestradiol
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01508858 ↗